Story Cannabis, an Arizona dispensary chain, has stopped accepting products tested by two laboratories recently cited by state regulators for inaccurate results.
The company sent an email to vendors informing them it would no longer accept products with certificates of analysis from Kaycha Labs and Level One Labs, according to documents obtained by the Arizona Republic. The decision came after both facilities received citations from the Arizona Department of Health Services for testing violations.
The move highlights ongoing concerns about testing accuracy in state-licensed cannabis markets, where lab results determine whether products can be sold and what potency levels appear on packaging. Consumers rely on these certificates to make informed purchasing decisions about THC content, contaminants, and pesticide levels.
The Testing Problem
Arizona's regulatory action against the two labs adds to a pattern of testing issues that have plagued cannabis markets nationwide. Labs face pressure to deliver results that satisfy both regulators and clients, creating potential conflicts of interest when dispensaries shop for favorable numbers.
The state's citation details have not been fully disclosed, but testing violations typically involve inaccurate potency measurements, failure to detect contaminants, or improper laboratory procedures. These problems can lead to mislabeled products reaching consumers or unsafe cannabis passing inspection.
Story Cannabis operates multiple locations across Arizona and has positioned itself as a quality-focused brand. The company's decision to cut ties with the labs goes beyond minimum regulatory requirements, since the state has not revoked either facility's license.
Industry Response
Other Arizona dispensaries have not publicly announced similar actions, though the citations may prompt vendors to reassess their testing partnerships. Switching labs mid-stream can create supply chain complications, as products must be retested before sale.
Kaycha Labs operates facilities in multiple states and has faced scrutiny in other markets. Level One Labs is based in Arizona and serves the state's medical and adult-use cannabis industry.
Neither laboratory has issued a public statement about the citations or Story Cannabis's decision. The Arizona Department of Health Services has not announced whether additional enforcement actions are planned.
What's Next
The situation puts pressure on Arizona's cannabis testing framework, which requires all products to undergo third-party analysis before retail sale. State regulators conduct periodic audits of testing facilities but rely heavily on labs to self-report problems.
Industry advocates have called for more stringent oversight of testing labs, including blind sample testing and stricter penalties for violations. Some states have revoked licenses from labs with repeated accuracy problems, though Arizona has historically taken a lighter enforcement approach.
Story Cannabis has not specified how long the ban on products from the two labs will remain in effect or what criteria would need to be met for reinstatement. Vendors working with the dispensary chain will need to use alternative testing facilities to maintain their shelf space.
The Arizona market generated over $1.4 billion in sales last year, with testing requirements applying to all products in the supply chain. Any disruption to the testing infrastructure could create bottlenecks for producers trying to get products to market.
This article is based on original reporting by ganjapreneur.com.
